<DOC>
	<DOCNO>NCT00466219</DOCNO>
	<brief_summary>The aim study ass whether patient recurrent hepatitis C liver transplantation benefit treatment ribavirin/PEG-IFN-alpha combine treatment 48 week .</brief_summary>
	<brief_title>Ribavirin/Pegasys Treatment Recurrent Hepatitis C After Liver Transplant</brief_title>
	<detailed_description>The aim study ass whether patient fulfil criterion define section 3 benefit treatment ribavirin/PEG-a-IFN combine treatment . This study open patient histologically document hepatitis C recur LT , provide inclusion exclusion criterion , define , meet , irrespectively pattern response previous antiviral treatment ( ) . The benefit assess term biochemical ( normalization serum transaminase level ) , virological ( disappearance HCV RNA serum ) histological ( amelioration histological sign hepatitis ) response . The presence sustain virological response , define section 6 , also study relation early kinetics serum HCV RNA , keep recent data obtain chronic hepatitis C patient , suggest early rapid decrease HCV viremia associate durable response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>18 65 year old patient , male female , undergone LT endstage liver disease due HCV patient present LT recurrent HCV infection , document presence HCV RNA serum , recurrent hepatitis , diagnosed histology ; liver biopsy upon diagnosis establish must perform within 12 month prior inclusion ; treatment start within 6 month follow LT alpha fetoprotein value within normal limit obtain within 3 month entry visit stable immunosuppressive regimen , define lack therapeutic measure aim prevent treat graft rejection three month prior antiviral therapy participation clinical trial within 30 day entry protocol patient retransplanted rejection recurrent hepatitis C graft patient history cardiovascular disease include limited uncontrolled hypertension , angina pectoris , myocardial infarction , coronary artery surgery congestive heart failure exclude presence HBsAg and/or HIV history autoimmune disease , include autoimmune hepatitis alcohol consumption exceed 40 gram per day acute rejection episode within 3 month prior inclusion , current histological feature possibly relate underlying rejection hepatocellular carcinoma unresolved biliary complication renal insufficiency ( serum creatinine level 200 micromol/l ) unconjugated bilirubin blood level &gt; 100 micromol/l gammaglutamyl transferase &gt; 20 time upper limit normal range prothrombin time 60 % control ( except case oral anticoagulant therapy ) neutrophil count le 1,500/mm3 platelet count le 90,000/mm3 hemoglobin low limit normal test laboratory organ bone marrow transplantation current neoplasm and/or antitumor chemotherapy current hepatic arterial thrombosis pregnant breast feeding woman ; child bear potential woman without adequate contraception throughout course therapy psychosis antidepressant therapy uncontrolled clinical depression clinically significant retinal abnormality thyroid dysfunction ( abnormal TSH value without clinical symptom ) immunosuppressive therapy OKT3 antilymphocyte serum drug abuse ( heroin , cocaine ) substitution therapy 12 month prior inclusion history ischemic cardiopathy interstitial pneumonitis previous autoimmune hemolysis cause chronic hemolysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Presence HCV RNA serum</keyword>
	<keyword>Absence graft rejection</keyword>
	<keyword>Recurrent hepatitis C liver transplantation</keyword>
</DOC>